Your Health, We Care
December 20, 2024: The U.S. Food and Drug Administration (FDA) approved Pfizer’s Encorafenib combination regimen as the first-line treatment for BRAF V600E-mutant metastatic colorectal cancer.
October 11, 2023: The U.S. Food and Drug Administration (FDA) approved Encorafenib in combination with Binimetinib for the treatment of BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).
April 8, 2020: The U.S. Food and Drug Administration (FDA) approved Encorafenib in combination with Cetuximab for the treatment of BRAF V600E-mutant metastatic colorectal cancer (CRC) in patients who have received prior therapy.
June 27, 2018: Array BioPharma announced the U.S. Food and Drug Administration (FDA) approval of Encorafenib in combination with Binimetinib for the treatment of unresectable or metastatic melanoma with BRAF mutations.
